Cargando…
Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy
In oncotherapy, ruthenium (Ru) complexes are reflected as potential alternatives for platinum compounds and have been proved as encouraging anticancer drugs with high efficacy and low side effects. Cardiovascular diseases (CVDs) are mutually considered as the number one killer globally, and thrombos...
Autores principales: | Jayakumar, Thanasekaran, Hsu, Chia-Yuan, Khamrang, Themmila, Hsia, Chih-Hsuan, Hsia, Chih-Wei, Manubolu, Manjunath, Sheu, Joen-Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032250/ https://www.ncbi.nlm.nih.gov/pubmed/29925802 http://dx.doi.org/10.3390/ijms19061818 |
Ejemplares similares
-
Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling
por: Khamrang, Themmila, et al.
Publicado: (2017) -
Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets
por: Hsia, Chih-Hsuan, et al.
Publicado: (2018) -
Structure–Activity Relationship Study of Newly Synthesized Iridium-III Complexes as Potential Series for Treating Thrombotic Diseases
por: Yang, Chih-Hao, et al.
Publicado: (2018) -
A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies
por: Hsia, Chih-Hsuan, et al.
Publicado: (2017) -
Author Correction: A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies
por: Hsia, Chih-Hsuan, et al.
Publicado: (2020)